Table 2 VA change from baseline at 12 and 18 months after switching to brolucizumab
Cohort | VA change from baseline mean (95% CI) ETDRS letters | P-value |
|---|---|---|
12-month brolucizumab cohort (N = 174 eyes)* | − 1.1 (− 3.7, 1.6) | 0.42 |
Baseline injection interval sub-groups | ||
< 8 weeks ( n = 120 eyes) | − 1.7 (− 4.9, 1.5) | 0.30 |
≥ 8 weeks (n = 54 eyes) | 0.3 (− 4.4, 4.9) | 0.90 |
Baseline VA sub-groups (ETDRS letter range) | ||
Eyes with the best baseline VA (74.1–85.0 letters; n = 43 eyes) | − 3.7 (− 7.3, − 0.1) | 0.04 |
Eyes with better baseline VA (65.1–74.2 letters; n = 40 eyes) | − 2.0 (− 6.7, 2.7) | 0.39 |
Eyes with worse baseline VA (53.9–65.1 letters; n = 48 eyes) | − 1.6 (− 4.9, 1.8) | 0.37 |
Eyes with the worst baseline VA (19.9–53.9 letters; n = 43 eyes) | + 3.0 (− 3.3, 9.2) | 0.35 |
ETDRS letter vision change from baseline at Month 12 | n (%) | |
≥ 30 letters gained | 3 (1.7) | – |
≥ 15 to < 30 letters gained | 13 (7.5) | – |
≥ 5 to < 15 letters gained | 26 (14.9) | – |
< 5 letters lost to < 5 letters gained | 94 (54.0) | – |
≥ 5 to < 15 letters lost | 19 (10.9) | – |
≥ 15 to < 30 letters lost | 7 (4.0) | – |
≥ 30 letters lost | 10 (5.7) | – |
VA change from baseline mean (95% CI) ETDRS letters | P-value | |
|---|---|---|
18-month brolucizumab cohort (N = 95 eyes)** | 0.0 (− 3.1, 3.1) | 0.98 |
Baseline injection interval sub-groups | ||
< 8 weeks (n = 69 eyes) | − 0.1 (− 3.3, 3.0) | 0.94 |
≥ 8 weeks (n = 26 eyes) | 0.2 (− 8.0, 8.3) | 0.97 |
Baseline VA sub-groups (ETDRS letter range) | ||
Eyes with the best baseline VA (76.2–85.0 letters; n = 21 eyes) | − 5.5 (− 10.0, -0.9) | 0.02 |
Eyes with better baseline VA (67.1–76.2 letters; n = 27 eyes) | − 2.6 (− 5.6, 0.4) | 0.08 |
Eyes with worse baseline VA (58.8–67.1 letters; n = 23 eyes) | 1.8 (− 1.6, 5.1) | 0.29 |
Eyes with the worst baseline VA (19.9–58.8 letters; n = 24 eyes) | 5.9 (− 3.0, 14.8) | 0.18 |
ETDRS letter vision change from baseline at Month 18 | n (%) | |
≥ 30 letters gained | 2 (2.1) | – |
≥ 15 to < 30 letters gained | 8 (8.4) | – |
≥ 5 to < 15 letters gained | 12 (12.6) | – |
< 5 letters lost to < 5 letters gained | 47 (49.5) | – |
≥ 5 to < 15 letters lost | 20 (21.1) | – |
≥ 15 to < 30 letters lost | 3 (3.2) | – |
≥ 30 letters lost | 3 (3.2) | – |